SynthesisInflammatory bowel diseases2022
Epidemiology and Natural History of Perianal Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts.
Synthesis in Inflammatory bowel diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 4 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- Perianal fistulizing Crohn's disease: Clinical practice update from Colitis and Crohn's Foundation (India).Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Guideline
- Fistula Outcomes After Seton Removal in Patients with Perianal Fistulizing Crohn's Disease: A Systematic Review and Meta-Analysis.Digestive diseases and sciences · 2026Pooled it
- Treatment of perianal abscess and anal fistula in infants: a systematic review.Frontiers in surgery · 2025Pooled it
- Does Combined Medical and Surgical Treatment Improve Perianal Fistula Outcomes in Patients With Crohn's Disease? A Systematic Review and Meta-Analysis.Journal of Crohn's & colitis · 2024Pooled it
- Intraoperative Autologous Platelet-Rich Stroma Injection as Add-On to Fistula Curettage and Closure of the Internal Orifice Demonstrates a Favorable Outcome in Long-Term in Patients Suffering from Therapy-Refractory Perianal Fistulizing Crohn's Disease.Inflammatory bowel diseases · 2025Trial
- The Impact of Fistulizing Disease, Treatment Modalities, and Clinical Activity on Health-Related Quality of Life in Crohn's Disease.Digestive diseases and sciences · 2026Article
- Article
- Editorial: Upadacitinib in Perianal Crohn's Disease.Alimentary pharmacology & therapeutics · 2026Article
- Comment on "Type 1 Dolichocolon as a Potential Anatomic Co‑morbidity in Children with Perianal Crohn's Disease".Digestive diseases and sciences · 2026Article
- Addressing real-world data gaps: estimating the uk population cost of crohn's disease and ulcerative colitis using a flexible cost-of-illness model informed by the optimal patient journey and IBDUK patient survey 2023.BMC health services research · 2026Article
- Nomogram for predicting 6-month BMIZ changes in children with Crohn's disease: a single-center retrospective study.BMC pediatrics · 2026Article
- Type 1 Dolichocolon as a Potential Anatomic Co-morbidity in Children with Perianal Crohn's Disease.Digestive diseases and sciences · 2026Article
- One-Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real-World GETAID Study.Alimentary pharmacology & therapeutics · 2026Article
- Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID.The American journal of gastroenterology · 2026Article
- Effect of Perianal Disease on Quality of Life, Fecal Incontinence, and Sexual Function in Patients with Crohn's Disease.Digestive diseases and sciences · 2026Article
- Evolution of surgical trends in Crohn's disease during the biologic era: population-based cohort insights from Taiwan, a low-endemicity region.Intestinal research · 2026Article
- When nothing else matters: proctectomy for complex perianal Crohn's disease-indications, timing, techniques, and outcomes.Techniques in coloproctology · 2026Review
- Study protocol and statistical analysis plan for a randomized controlled trial evaluating the safety and feasibility of the recombinant human platelet-derived growth factor B (rhPDGF-BB)-enhanced collagen plug for complex perianal fistula healing.medRxiv : the preprint server for health sciences · 2026Article
- Fistulotomy for superficial or minimal sphincter-involving fistulae in perianal Crohn's disease: do they heal?Techniques in coloproctology · 2026Article
- Advancement flaps in perianal fistulizing Crohn's disease: technical steps and current evidence.Techniques in coloproctology · 2026Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimsPerianal Crohn's disease (pCD) is a potentially severe phenotype of CD. We conducted a systematic review with meta-analysis to estimate cumulative incidence, risk factors, and outcomes of pCD in population-based cohort studies.
methodsThrough a systematic literature review through March 1, 2021, we identified population-based inception cohort studies reporting cumulative incidence of perianal disease (primarily abscess and/or fistula) in patients with CD. We estimated the cumulative incidence of pCD at presentation and 1-, 5-, and 10-year follow-up, and risk factors for perianal disease and outcomes including risk of major (bowel resection, proctectomy, ostomy) and minor perianal (incision and drainage, seton placement, etc.) surgery.
resultsIn 12 population-based studies, prevalence of pCD was 18.7% (95% confidence interval [CI], 12.5%-27.0%) with 1-, 5-, and 10-year risk of perianal disease being 14.3% (95% CI, 7.9%-24.6%), 17.6% (95% CI, 11.3%-26.5%), and 18.9% (95% CI, 15.0%-23.4%), respectively. Approximately 11.5% of patients (95% CI, 6.7%-19.0%) had perianal disease at or before CD diagnosis. Colonic disease location and rectal involvement were associated with higher risk of pCD. Overall, 63.3% of patients (95% CI, 53.3-72.3) required minor perianal surgery and 6.4% of patients (95% CI, 1.8%-20.6%) required major abdominal surgery for pCD. Use of biologic therapy for pCD is common and has steadily increased throughout the years.
conclusionsApproximately 1 in 5 patients with CD develops perianal disease within 10 years of CD diagnosis, including 11.5% who have perianal disease at presentation. Approximately two-thirds of patients require perianal surgery, with a smaller fraction requiring major abdominal surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.